Suchergebnisse
10
Alles
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
31. März 2025 08:00 ET
|
Monopar Therapeutics Inc.
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with...
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
20. März 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Introduces REYOBIQ™, FDA-Accepted Proprietary Name for Lead Drug Candidate
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
10. März 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Nasdaq Minimum Stockholders’ Equity Requirement
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda in Glioblastoma
07. März 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Peer-Reviewed Publication in Nature Communications Highlighting Promising Phase 1 Results for Rhenium (186Re) Obisbemeda
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with Lung Cancer
06. März 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Granted U.S. FDA Orphan Drug Designation for Rhenium (186Re) Obisbemeda for the Treatment of Leptomeningeal Metastases in Patients with L
Plus Therapeutics Announces New Employment Inducement Grants
05. März 2025 16:01 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces New Employment Inducement Grants
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
04. März 2025 14:06 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
04. März 2025 06:35 ET
|
Y-mAbs Therapeutics, Inc.
Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
24. Februar 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer
20. Februar 2025 07:30 ET
|
Plus Therapeutics Inc.
Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer